All translations
Jump to navigation
Jump to search
Enter a message name below to show all available translations.
Found 2 translations.
| Name | Current message text |
|---|---|
| h English (en) | Endogenous GLP-1 is rapidly degraded primarily by [[dipeptidyl peptidase-4]] (DPP-4), as well as neutral endopeptidase 24.11 (NEP 24.11) and [[renal clearance]], resulting in a [[half-life]] of approximately 2 minutes. Consequently, only 10–15 % of GLP-1 reaches circulation intact, leading to fasting plasma levels of only 0–15 pmol/L. To overcome this, [[GLP-1 receptor agonist]]s and [[DPP-4 inhibitors]] have been developed to increase GLP-1 activity. As opposed to common treatment agents such as [[insulin]] and [[sulphonylurea]], GLP-1-based treatment has been associated with [[weight loss]] and a lower risk of [[hypoglycemia]], two important considerations for patients with type 2 diabetes. |
| h Japanese (ja) | 内因性GLP-1は主に[[dipeptidyl peptidase-4/ja|ジペプチジルペプチダーゼ-4]]（DPP-4）と中性エンドペプチダーゼ24.11（NEP24.11）および[[renal clearance/ja|腎クリアランス]]によって速やかに分解され、その結果、[[half-life/ja|半減期]]は約2分となる。その結果、GLP-1の10～15％しかそのまま循環に到達しないため、空腹時の血漿中濃度は0～15pmol/Lにしかならない。これを克服するために、GLP-1活性を高める[[GLP-1 receptor agonist/ja|GLP-1受容体作動薬]]や[[DPP-4 inhibitors/ja|DPP-4阻害薬]]が開発されてきた。[[insulin/ja|インスリン]]や[[sulphonylurea/ja|スルホニルウレア]]などの一般的な治療薬とは対照的に、GLP-1ベースの治療は[[weight loss/ja|体重減少]]と[[hypoglycemia/ja|低血糖]]のリスクの低下と関連しており、2型糖尿病患者にとって重要な2つの考慮事項である。 |